title: What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?
abstract: PURPOSE, PATIENTS AND METHODS: This retrospective analysis of the BRAVE study evaluated the impact of baseline risk factors and antithrombotic therapy on the risk of thrombovascular events (TVEs) in patients receiving epoetin compared to patients not receiving epoetin.
  
  
  RESULTS
  Baseline risk factors have a significant impact on TVE risk under epoetin therapy. More than 2 risk factors increased the risk of TVEs in patients receiving epoetin (hazard ratio [HR] 2.89, confidence interval [CI] 1.04-8.02, p value [p]=0.04). In patients on epoetin without antithrombotic therapy, the risk for TVEs was higher (HR 4.11, CI 1.37-12.4, p=0.01) compared to those who received antithrombotics (HR 1.37, CI 0.59-3.18, p=0.45).
  
  
  CONCLUSIONS
  Our analysis has identified several risk factors which may impact the risk of TVEs under epoetin therapy. These data suggest that antithrombotic therapy may have the potential to reduce the risk of TVEs under epoetin therapy. These findings are hypothesis-generating and need to be confirmed in a prospective, randomised study.
authors: Institut Multidisciplinaire d'Oncologie, Clinique de Genolier, CH-1272 Genolier, Switzerland. maapro@genolier.net
authors: Matti
authors: M
authors: Aapro
authors: Agustí
authors: A
authors: Barnadas
authors: Robert C
authors: RC
authors: Leonard
authors: Maurizio
authors: M
authors: Marangolo
authors: Michael
authors: M
authors: Untch
authors: Lidia
authors: L
authors: Ukarma
authors: Hans-Ulrich
authors: HU
authors: Burger
authors: Armin
authors: A
authors: Scherhag
authors: Bruno
authors: B
authors: Osterwalder
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000150:complications*; D004812:Epidemiologic Methods; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D011994:Recombinant Proteins; D013924:Thrombophlebitis / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D013927:Thrombosis / Q000139:chemically induced / Q000209:etiology* / Q000517:prevention & control
chemical_list: D005343:Fibrinolytic Agents; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin